CellSource Co., Ltd. (JP:4880)
:4880
Top Page
CellSource Co., Ltd.
(4880)
Select Model
Select Model
Rating:58Neutral
Price Target:
¥388.00
▼(-2.76% Downside)
Action:ReiteratedDate:03/24/26
The score is supported primarily by a conservative, low-debt balance sheet and continued positive cash generation, but is held back by sharply weaker profitability/returns, a technically weak price trend below major moving averages, and a high P/E that looks demanding given current earnings strength.
Positive Factors
Conservative balance sheet
CellSource's minimal leverage and high equity base give durable financial flexibility to fund R&D, manufacturing and partnerships without heavy reliance on external debt. This conservatism improves resilience through biotech revenue cycles and supports strategic investments over the medium term.
Negative Factors
Sharp profitability deterioration
Profitability and returns have eroded materially, with net margin collapsing to near break-even. Sustained weak margins constrain reinvestment, limit ability to fund growth organically, and create pressure to restructure costs or seek external capital to restore returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
CellSource's minimal leverage and high equity base give durable financial flexibility to fund R&D, manufacturing and partnerships without heavy reliance on external debt. This conservatism improves resilience through biotech revenue cycles and supports strategic investments over the medium term.
Read all positive factors
CellSource Co., Ltd. (4880) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.92B
Dividend Yield1.24%
Average Volume (3M)77.65K
Price to Earnings (P/E)59.4
Beta (1Y)0.83
Revenue Growth-14.78%
EPS Growth-95.53%
CountryJP
Employees151
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.70
Shares Outstanding19,847,778
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.83
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.1
Revenue Forecast (FY)¥3.45B
CellSource Co., Ltd. Business Overview & Revenue Model
Company Description
CellSource Co., Ltd. engages in the regenerative medicine-related and consumer businesses. It also offers Signalift, an anti-aging product. The company was incorporated in 2015 and is headquartered in Tokyo, Japan....
How the Company Makes Money
null...
CellSource Co., Ltd. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
85
Very Positive
Cash Flow
62
Positive
| Breakdown | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.71B | 4.36B | 4.51B | 4.27B | 2.92B |
| Gross Profit | 2.09B | 2.36B | 3.16B | 3.05B | 2.06B |
| EBITDA | 371.03M | 282.38M | 1.29B | 1.63B | 1.05B |
| Net Income | 10.66M | 237.94M | 923.14M | 1.02B | 651.40M |
Balance Sheet | |||||
| Total Assets | 7.11B | 7.17B | 6.89B | 4.60B | 3.37B |
| Cash, Cash Equivalents and Short-Term Investments | 4.71B | 4.32B | 4.78B | 3.12B | 2.41B |
| Total Debt | 56.72M | 77.29M | 97.54M | 0.00 | 1.10M |
| Total Liabilities | 1.10B | 1.13B | 689.49M | 815.72M | 645.58M |
| Stockholders Equity | 6.02B | 6.04B | 6.20B | 3.79B | 2.72B |
Cash Flow | |||||
| Free Cash Flow | 289.90M | 98.47M | 498.62M | 752.89M | 843.36M |
| Operating Cash Flow | 333.10M | 591.72M | 846.69M | 847.60M | 898.19M |
| Investing Cash Flow | -3.29M | -614.96M | -624.08M | -169.39M | -256.12M |
| Financing Cash Flow | 61.07M | -437.24M | 1.45B | 14.42M | 9.35M |
CellSource Co., Ltd. Technical Analysis
Neutral
399.00
Price Trends
394.34
Positive
421.59
Negative
517.74
Negative
Market Momentum
1.14
Negative
52.87
Neutral
88.53
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4880, the sentiment is Neutral. The current price of 399 is above the 20-day moving average (MA) of 388.30, above the 50-day MA of 394.34, and below the 200-day MA of 517.74, indicating a neutral trend. The MACD of 1.14 indicates Negative momentum. The RSI at 52.87 is Neutral, neither overbought nor oversold. The STOCH value of 88.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4880.
CellSource Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥7.92B | 59.41 | ― | 1.24% | -14.78% | -95.53% | |
56 Neutral | ¥17.31B | 120.78 | ― | ― | 1.24% | -33.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥24.57B | -34.16 | ― | ― | -5.65% | -469.19% | |
50 Neutral | ¥49.01B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.31B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥19.24B | -11.30 | ― | ― | ― | 11.34% |
* Healthcare Sector Average
JP:4880
CellSource Co., Ltd.
399.00
-210.88
-34.58%
JP:4593
Healios KK
363.00
127.00
53.81%
JP:4599
StemRIM Inc.
307.00
37.00
13.70%
JP:4978
ReproCELL Inc.
182.00
51.00
38.93%
JP:7774
Japan Tissue Engineering Co., Ltd.
605.00
196.00
47.92%
JP:7776
CellSeed Inc.
291.00
-234.00
-44.57%
CellSource Co., Ltd. Corporate Events
CellSource to Shift Listing to TSE Standard Market After Missing Prime Criteria
Mar 17, 2026
CellSource Co., Ltd. has received approval from the Tokyo Stock Exchange to transfer its listing from the Prime Market to the Standard Market, effective March 24, 2026, after failing to meet the Prime segment’s tradable share market capitali...
CellSource Returns to Quarterly Profit but Keeps Forecast for Full-Year Loss
Mar 17, 2026
CellSource reported consolidated net sales of ¥860 million for the three months ended January 31, 2026, a modest 1.3% year-on-year increase, and swung to an operating and ordinary profit of ¥59 million with profit attributable to owners ...
CellSource Sees January Contract Processing Growth Led by Hybrid Orthopedics
Feb 9, 2026
CellSource Co., Ltd. operates in the medical and biotechnology services sector, focusing on contract processing of blood-derived products for clinical applications. Its primary business serves departments such as self-funded and hybrid orthopedics...
CellSource to Shift Listing to TSE Standard Market After Falling Short of Prime Criteria
Jan 28, 2026
CellSource has disclosed that, as of October 31, 2025, it no longer meets the Prime Market’s continued listing criterion for market capitalization of tradable shares, although it continues to satisfy the other Prime Market requirements. To a...
CellSource Seeks Shift From TSE Prime to Standard Market After Performance Slump
Jan 28, 2026
CellSource Co., Ltd. has resolved to apply to move its listing from the Tokyo Stock Exchange Prime Market to the Standard Market after weak business performance in the fiscal year ended October 31, 2025 caused it to fall below the Prime MarketR...
CellSource Sees December Contract Processing Orders Rise on Hybrid Orthopedics Growth
Jan 14, 2026
CellSource reported that its daily average number of contract processing orders in December 2025 rose year-on-year to 48.0, driven mainly by growth in hybrid orthopedics and aesthetic medicine despite declines in self-funded orthopedics and OBGYN ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.